Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Conestoga Mid Cap Composite 2025 Q1 Investor Letter | Buyside Digest

Back to Fund Profile (Conestoga Mid Cap Composite)

Primary Source Intelligence • Q1 2025 Letter Analysis

Conestoga Mid Cap Composite Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Conestoga Mid Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+0.96%

Annualized+11.17%

Positioning StanceConstructive

Market CapMid Cap

GeographyUS

Digest Analysis

Quick Take

"Conestoga's Mid Cap strategy outperformed significantly in Q1 2025.12% decline. The portfolio's emphasis on high-quality, recession-resistant companies with recurring revenue and strong cash flows proved advantageous during market volatility."

Executive Summary

Conestoga's Mid Cap Composite delivered strong relative performance in Q1 2025, rising 0.96% while the Russell Midcap Growth Index declined 7.12%. The strategy's emphasis on higher-quality, conservative growth companies with recurring revenue streams and stable business models proved advantageous during the market selloff. Stock selection drove the entirety of outperformance, with particular strength in Consumer Discretionary, Industrials, and Technology sectors. Key contributors included Rollins and Bright Horizons in Consumer Discretionary, HEICO and Verisk in Industrials, and Roper Technologies and Guidewire in Technology. The portfolio benefited from avoiding semiconductor and computer hardware exposure while focusing on software companies. Healthcare was the only sector with negative stock selection, primarily due to West Pharmaceutical Services' disappointing guidance. The strategy's focus on recession-resistant companies with strong free cash flow generation and defensive characteristics resonated with investors during the volatile quarter, validating the firm's patient, long-term investment approach.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

75%

CautiousHigh

High Conviction (75%)

The commentary demonstrates high conviction through specific company analysis, clear articulation of investment thesis, selective portfolio adjustments, and explicit statements of maintaining 'high conviction' in holdings despite near-term headwinds. The detailed attribution analysis and forward-looking statements reflect strong belief in the strategy.

Growth Outlook

38%

BearishBullish

Neutral (38%)

The commentary acknowledges challenging market conditions with equity selloffs, geopolitical tensions, and tariff uncertainties, but also notes that some macroeconomic headwinds appear to be abating and management sees opportunities for M&A activity, suggesting a cautiously negative but not deeply pessimistic market view.

Risk Appetite

10%

DefensiveAggressive

Defensive (10%)

The portfolio maintained its focus on high-quality, defensive companies and made selective position adjustments (selling ALGN and reinvesting in higher conviction holdings), indicating a balanced to slightly risk-on positioning with emphasis on quality over aggressive growth.

Capital Deployment

10%

De-riskingDeploying

De-risking (10%)

Limited deployment activity with one sale (ALGN) and reinvestment into higher conviction holdings. No new positions were added, and no cash level changes were mentioned, indicating selective rebalancing rather than aggressive deployment or de-risking.

Forward Guidance

15%

CautiousExpansionary

Cautious (15%)

Management expresses optimism about M&A opportunities at reasonable prices and believes macroeconomic headwinds are abating for several portfolio companies, while maintaining high conviction in holdings despite near-term challenges, suggesting a cautiously positive forward bias.

Language Signal

5%

BearishBullish

Bearish (5%)

The language balances acknowledgment of market challenges with confidence in the strategy's positioning and individual company prospects. Terms like 'recession-resistant,' 'defensive characteristics,' and 'high conviction' suggest measured optimism despite market volatility.

Perceived Risk

60%

Low RiskElevated

Moderate Risk (60%)

The commentary acknowledges multiple risk factors including earnings slowdowns, geopolitical tensions, tariff uncertainties, and regulatory/funding environment concerns affecting healthcare companies. However, these are presented as manageable challenges rather than systemic threats.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

Management sees selective opportunities including M&A activity at reasonable prices and believes macroeconomic headwinds are abating for several companies. The focus on high-quality companies suggests opportunities exist but require selectivity rather than broad-based deployment.

Time Horizon

80%

Short-TermLong-Term

Decade+ (80%)

The strategy emphasizes long-term investment approach, patient capital allocation, and maintaining conviction despite near-term headwinds. References to companies recovering from pandemic impacts and multi-year business cycles indicate a patient, long-term orientation.